Abstract 439P
Background
Ewing’s sarcoma and osteosarcoma have high incidence in teenage and young adults (TYA) with age range(15-29 years). This study investigated the epidemiology of cancers among TYA population,with a special emphasis on Ewing’s sarcoma, evaluating theimpact of symptom delay and system delay variables on the patient outcomes.
Methods
This was a single-center, retrospective cross-sectional study conducted between June 2015 and March 2020 on TYA patients with a confirmed diagnosis of cancer. TYA patients registered with Ewing’s sarcoma were selected for the study using a non-probability sampling technique. The symptom delay was defined as >1 month duration from the first symptom to the consultation by primary care physician (PCP). The system delay was defined as >1 month duration from initial consultation by PCP to referring the patient to a dedicated cancer center.
Results
Our study gives a comprehensive overview of cancer epidemiology among TYA patients. Our observation is that 7.35% (450/6120) of our cancer patients are TYAs. Ewing’s sarcoma was found in 8.88% (40/450) of all the TYA cancer patients.Symptom delay was noted among 65.0% of patients and system delay occurred among 57.5% of patients. We observed that symptom delay and system delay at presentation had a significant impact on the patient outcome in terms of increased metastasis and reduced progression free survival. Patients with large tumor volume (>100 cc) had poor Progression Free Survival (PFS), showing a strong negative correlation between tumor volume and PFS. Mean five-year PFS for patients with no detectable metastatic disease at diagnosis was significantly better than for those with metastases (59m vs. 19m, respectively; P<.001). Table: 439P
Correlation of PFS with clinical variables
Parameter | Variable | n | PFS (months) Mean ±SD | p-value | ||
Localized Disease | No | 15 | 18.93±8.74 | p<0.001 | ||
Yes | 25 | 59.28±16.09 | ||||
Symptom Delay in Survived | No | 14 | 69.07±10.12 | p<0.001 | ||
Yes | 16 | 40.69±15.19 | ||||
System Delay in Survived | No | 16 | 66.94±12.20 | p<0.001 | ||
Yes | 14 | 39.07±14.62 |
Conclusions
Ewing’s sarcoma should be considered the prototype of a TYA cancer. Efforts in improving access to healthcare facilities, education of primary healthcare physicians, pediatricians and orthopedic surgeons is of paramount importance to facilitate an early diagnosis and establish care pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
419P - Breast arterial calcifications on mammogram and its clinical implications
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
420P - Predictive factors of post-operative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: A retrospective cohort study
Presenter: Chito Cabiling
Session: Poster viewing 06
421P - The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Presenter: Deniz Can Guven
Session: Poster viewing 06
422P - Molecular mechanism in prostate cancer with TP53 mutation
Presenter: Bin Hu
Session: Poster viewing 06
423P - Maintaining a national essential medicine list for cancer in Malaysia: Where do we stand?
Presenter: David Lee
Session: Poster viewing 06
424P - The Storm: Paraneoplastic leucomoid reaction - A bad prognostic factor
Presenter: Abdullah Al Mamun Khan
Session: Poster viewing 06
425P - Preliminary study: Assessment of public trust in traditional medicine and medical treatment in cancer patients in Indonesia - Study validity and reliability of the Universitas Sebelas Maret Trust and readiness assessment for cancer patients (UNS – TRAfCP35) questionnaire
Presenter: Widyanti Soewoto
Session: Poster viewing 06
426P - Safety of Sputnik V COVID-19 vaccine in cancer patients receiving chemotherapy: An observational study
Presenter: Alexey Rumyantsev
Session: Poster viewing 06
427P - Oncology combination therapies in Asia-Pacific markets: What are the current access challenges?
Presenter: Gayathri Kumar
Session: Poster viewing 06
428P - Clinical characteristics, laboratory parameters, and hospital outcomes of COVID-19 among patients with and without cancer: A retrospective cohort study
Presenter: PRASHANT SIROHIYA
Session: Poster viewing 06